Twist Bioscience Reports Fiscal Second Quarter 2025 Financial Results - Record revenue of $92.8M in 2QFY25; Increase of 23% over $75.3M in 2QFY24, 9th consecutive quarter of sequential growth - - Gross margin of 49.6% in

Twist Bioscience Reports Fiscal Second Quarter

2025 Financial Results

- Record revenue of $92.8M in 2QFY25; Increase

of 23% over $75.3M in 2QFY24,

9th consecutive quarter of sequential growth -

- Gross margin of 49.6% in 2QFY25 versus

41.0% in 2QFY24; Improvement of 8.6 margin percentage points -

- Expect revenue in the range of $372 million

to $379 million for full year fiscal 2025; expect gross margin over 50% for 4QFY25 -

- Spins out DNA Data Storage as Atlas Data

Storage with $155M investment from ARCH Venture Partners, Deerfield Management, Bezos Expeditions, TAO Capital Partners, Earth Foundry,

Rsquared VC, In-Q-Tel (IQT) and others -

-Expect to achieve adjusted EBITDA breakeven

on accelerated timeline by end of fiscal 2026 -

SOUTH SAN FRANCISCO, Calif. -- (May 5, 2025) -

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health

care sector, today reported financial results and business highlights for the second quarter of fiscal 2025 ended March 31, 2025.

Separately, Twist announced the spin out of its DNA storage application as an independent company, Atlas Data Storage, with funding from

leading strategic partners and investors.

"I'm extremely excited to announce the launch of Atlas

Data Storage to advance the development of DNA data storage while allowing Twist to accelerate our journey toward profitability,"

said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "By operating as two separate companies, we maintain sharp

focus, with each organization dedicated to developing and commercializing disruptive products and services, while prioritizing exceptional

customer engagement."

Dr. Leproust continued, "Our announcement this morning complements

our second quarter results as we reported our ninth consecutive quarter of sequential growth and record

performance across revenue, gross margin and adjusted EBITDA. As we move through fiscal 2025, we'll continue to lead with innovation,

agility, and customer impact, as we focus on capturing market share and driving profitable growth."

See "Non-GAAP Information" below for a discussion of the

non-GAAP measure adjusted EBITDA.

FISCAL 2025 SECOND QUARTER FINANCIAL RESULTS

Updated Fiscal 2025 Financial Guidance

The following statements are based on Twist's current expectations

for fiscal 2025, including the third quarter of fiscal 2025. The following statements are forward-looking, and actual results could differ

materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below.

For the full fiscal year 2025, Twist expects:

For the third quarter, Twist expects:

Twist now expects to achieve adjusted EBITDA breakeven on an accelerated

timeline by the end of fiscal 2026.

Non-GAAP Information

This release includes EBITDA and adjusted EBITDA, which are non-GAAP

financial measures, for the periods presented. EBITDA is defined as net loss adjusted to exclude interest income, interest expense, income

tax expense and depreciation and amortization. Adjusted EBITDA is defined as net loss adjusted to exclude interest income, interest expense,

income tax expense, depreciation and amortization, other income/expense, net and stock-based compensation expense detailed in the reconciliation

table below that we believe are not indicative of our ongoing results. These non-GAAP measures are not in accordance with, or an alternative

for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures

used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.

Management believes that these non-GAAP financial measures, when considered together with our financial information prepared in accordance

with GAAP, can enhance investors' and analysts' ability to meaningfully compare our results from period to period and to our

forward-looking guidance, and to identify operating trends in our business. However, non-GAAP information is not superior to financial

measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical

tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. A reconciliation

table of the most comparable GAAP financial measure to the non-GAAP financial measure is included at the end of this press release.

A reconciliation of adjusted EBITDA for fiscal 2025 and the third quarter

of fiscal 2025 and fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because

the Company does not provide guidance on GAAP net loss and is not able to present the various reconciling cash and non-cash items between

GAAP net loss and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company's

future hiring and retention needs, as well as the future fair market value of its common stock, all of which is difficult to predict and

is subject to change. The actual amount of these expenses during fiscal 2025, the third quarter of fiscal 2025 and fiscal 2026 will have

a significant impact on Twist's future GAAP financial results.

Conference Call Information

The company plans to hold a conference call and live audio webcast

for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company's

business. The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com.

Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking

here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be

used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled

start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

At Twist Bioscience, we work in service of

customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using

our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our

customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis

Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies

and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality

and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services,

please visit www.twistbioscience.com.

| Instagram | Bluesky

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements

other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations

of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not

limited to, projections under the heading "Updated Fiscal 2025 Financial Guidance" statements regarding future growth and

expansion, revenue and gross margin growth, estimated annual revenues, ability and timing to achieve profitability, ability and timing

to achieve adjusted EBITDA breakeven and ability to increase gross margin, the expected benefits of the spin-out, expectations relating

to future contingent payments, expectations with respect to and Atlas Data Storage's ability to accelerate the development of DNA

data storage and Twist's other expectations regarding its future operations plans and financial performance, introduction of new

products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important

factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results,

performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others,

the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue

to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary;

risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist

is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical

component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts;

changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; risks associated

with the spin out of Atlas Data Storage; and the ability to maintain and enforce intellectual property protection. For a description of

the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well

as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K